Biotech · Preclinical

A preclinical cell therapy company removing the manufacturing step from CAR-T by engineering T cells inside the patient.

What they do

Conventional CAR-T requires extracting a patient’s T cells, engineering them in a specialized facility, and infusing them back, a process that takes weeks and costs six figures. Alaya’s platform delivers the CAR construct in vivo using a targeting polymeric nanoparticle: a lentiviral vector coated in a biodegradable polymer, designed to transduce quiescent cells such as T cells, NK cells, and stem cells. The technology works either ex vivo or in vivo.

Source: Businesswire

Key facts

•Stage: preclinical, with proof-of-concept data showing anti-tumoral efficacy in immunocompetent mouse models.

•October 2023: acquired from Ixaka France 12 patent families, the preclinical data package, exclusive licenses to the polymeric nanoparticle technology, and lab space plus viral vector bioproduction facilities in Paris.

•Headquarters: Cambridge, Massachusetts.

•Leadership: Renaud Vaillant, founder and CEO. Cécile Bauche, founder and Chief Scientific Officer.

What makes them different

The delivery vehicle is the product. Rather than competing on the CAR construct itself, Alaya competes on getting it into the right cell without a manufacturing suite, which is the cost and access bottleneck in the category.

Why KMAK invested

CAR-T works. The problem is that almost nobody can get it. A therapy that requires a cleanroom, a courier, and four weeks per patient will never reach the volume its clinical results deserve. Alaya is attacking the delivery layer rather than the biology, and a delivery platform that works is horizontally valuable across every CAR construct, not just its own. The Ixaka acquisition gave the company a patent estate and a bioproduction site for a fraction of what building them would cost. This is the earliest-stage position in our portfolio and we underwrote it that way.